口服塞马格卢提德 (Rybelsus) 开始后两周内发生深静脉血栓症:一个病例报告
Maamoun Alsermani1, Baraa Ali Alkahmous1, Arwa A Alhutayrashi2
1Hematology, Prince Mohammed Bin Abdulaziz Hospital, Riyadh, SAU.
Cureus
|February 6, 2026
概括
用于糖尿病和减肥的葡萄糖类-1受体激活剂 (GLP-1RAs) 可能与青少年血栓有关. 一个案例报告详细介绍了一名青少年在未经监督的情况下口服西马格卢提德后发展深静脉血栓症 (DVT).
科学领域:
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
- 血管医学 血管医学
背景情况:
- 类似葡萄糖-1受体激动剂 (GLP-1RAs) 广泛用于2型糖尿病和体重管理.
- 在青少年中,GLP-1RA的非标签使用正在增加.
- 新出现的数据表明GLP-1RAs与血栓塞栓事件之间存在潜在联系.
研究的目的:
- 在使用口服赛马格卢提德减肥的青少年中报告深静脉血栓形成病例.
- 要突出与未经监督的GLP-1RA在年轻成年人使用相关的潜在风险.
- 促使进一步调查GLP-1RAs与血栓形成之间的关联.
主要方法:
- 一个16岁的男性出现了急性左下肢DVT的病例报告.
- 在没有医疗监督的情况下开始服用口服赛马格卢提德 (每天7毫克) 减肥.
- 诊断工作包括双重超声波和血栓友爱查.
- 用抗凝剂治疗 (低分子量肝素,其次是阿皮克萨班).
主要成果:
- 青少年在开始服用口服赛马格卢提德的两周内出现了DVT.
- 双重超声波检查证实了距离表面大腿静脉和尾静脉的血栓形成.
- 血栓ophilia工作是负面的.
- 抗凝药导致显著的临床改善.
结论:
- 这一案例表明,口服赛马格卢提德与青少年静脉血栓形成之间存在潜在的关联.
- 对于非标签GLP-1RA的使用,特别是在年轻人中,仔细监督至关重要.
- 需要进一步的药监和机制研究来证实这种关联并阐明潜在的机制.
相关概念视频
Venous Thrombosis I: Introduction
474
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
474
Venous Thrombosis III: Interprofessional Care
373
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
373
Venous Thrombosis IV: Nursing Management
268
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
268
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
348
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
348
Data Reporting and Recording
5.5K
Reporting and recording are crucial in data documentation. The timely, thorough, and accurate documentation of facts is essential when recording patient data. Failure to record findings during an assessment or interpretation of a problem will result in loss of information and make the patient document unreliable. The reader is left with general impressions if the information is not specific. A recording is documenting data of the individual's health information in a traceable, secure, and...
5.5K
Initiation of Translation
39.1K
Initiating translation is complex because it involves multiple molecules. Initiator tRNA, ribosomal subunits, and eukaryotic initiation factors (eIFs) are all required to assemble on the initiation codon of mRNA. This process consists of several steps that are mediated by different eIFs.
First, the initiator tRNA must be selected from the pool of elongator tRNAs by eukaryotic initiation factor 2 (eIF2). The initiator tRNA (Met-tRNAi) has conserved sequence elements including modified bases at...
First, the initiator tRNA must be selected from the pool of elongator tRNAs by eukaryotic initiation factor 2 (eIF2). The initiator tRNA (Met-tRNAi) has conserved sequence elements including modified bases at...
39.1K


